Mark Ackermann

Director, Oregon Veterinary Diagnostic Laboratory

My research has emphasized respiratory disease and most noteably infections of human strains of respiratory syncytial virus (RSV) infection in newborn lambs as a model for human infants. There are no vaccines or currently effective therapies for RSV despite the fact that nearly everyone becomes infected with RSV and that it is the leading cause of hospitalization for viral pneumonia in human infants. For the last 15 years, we have characterized the kinetics of the development of clinical signs, lesions and viral parameters as well as adaptive and innate immune responses with funding from the USDA and NIH. For the last 7 years we have assessed various novel oral and nebulized therapies against RSV in collaboration with pharmaceutical and biotechnology companies as well as our own therapeutic approaches. Additional ongoing research activity includes inflammatory bowel disease of dogs and cats and previous research activity included: Mannheimia haemolytic pneumonia of cattle, Bovine Leukocyte Adhesion Deficiency of Holstein calves, Atrophic Rhinitis in pigs, E. coli infections in pigs, and Colisepticemia pneumonia/air sacculitis in turkeys.